Table 1 Clinical indicators between refractory and non-refractory group
Non-refractory group (27) | Refractory group (13) | P | |||
|---|---|---|---|---|---|
Total(n) | Proportion(%) | Total(n) | Proportion(%) | ||
Clinical syndromes | |||||
Gender(male: female) | 5:22 | 18.5 | 6:7 | 46.2 | 0.067 |
Cervical flexion weakness | 22 | 81.5 | 11 | 84.6 | 0.807 |
Severe myasthenia | 9 | 33.3 | 8 | 61.5 | 0.091 |
Dysphagia | 9 | 33.3 | 5 | 38.5 | 0.750 |
Dysmasesia | 7 | 25.9 | 1 | 7.7 | 0.177 |
Myalgia | 10 | 37.0 | 4 | 30.8 | 0.697 |
Amyotrophy | 11 | 40.7 | 6 | 46.2 | 0.746 |
Weight lost | 11 | 40.7 | 10 | 76.9 | 0.032 |
Auxiliary examination | |||||
ILD | 6 | 22.2 | 9 | 69.2 | 0.004 |
Elevated ESR | 5 | 18.5 | 5 | 38.5 | 0.872 |
Elevated ANA | 12 | 44.4 | 8 | 61.5 | 0.311 |
Combined with anti-Ro-52 antibody | 7 | 25.9 | 5 | 38.5 | 0.418 |
Initial therapy | |||||
GC | 3 | 11.1 | 4 | 30.8 | 0.132 |
GC + IVIg+MTX | 10 | 37.0 | 3 | 23.1 | 0.390 |
GC + MTX | 6 | 22.2 | 1 | 7.7 | 0.269 |
GC + IVIg | 5 | 18.5 | 3 | 23.1 | 0.744 |
GC + OI | 4 | 14.8 | 5 | 38.5 | 0.098 |
OI + MTX | 16 | 59.3 | 3 | 23.1 | 0.032 |
OI + IVIg | 15 | 55.6 | 6 | 46.2 | 0.588 |